Pilot Trial for WounDx™ Clinical Decision Support Tool
This study is testing a new medical device called WounDx™ (pronounced "wound-dex"). WounDx™ is a Clinical Decision Support Tool (CDST) that helps doctors decide if a large wound on an arm or leg is ready to be closed. It works by looking at information from your wound to create a report for the surgeon. The final decision to close the wound is always made by the surgeon. This trial will help us understand how well WounDx™ works in a hospital setting and if it can help improve wound healing. We are looking for 40 participants, aged 18 to 65, with large extremity wounds. The main goal is to see how many patients complete the study's measurements over one year.
- Study design
- This is an interventional pilot trial with a planned enrollment of 40 participants. It is testing the WounDx device alongside standard wound care.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for one year to measure the number of patients who complete the exploratory outcome measures.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Pilot Trial for WounDx™ Clinical Decision Support Tool
At a glance
Conditions
Where it's being run
5 sites across 5 statesStudy leadership
- Eric Elster, MD · PRINCIPAL_INVESTIGATOR · Uniformed Services University of the Health Sciences
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Number of Patients from Each Site that Completes the Exploratory Outcome Measures1 year
The primary outcome will be a report detailing the total number of patients from each site who have successfully completed all exploratory outcome measures. It is expected that a minimum of 3 patients from each site will complete required exploratory outcome measures.